ID: ALA3400479

Max Phase: Preclinical

Molecular Formula: C16H15N3O2S

Molecular Weight: 313.38

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CCN(c1cccc(OC)c1)c1nc(=O)c2cccnc2s1

Standard InChI:  InChI=1S/C16H15N3O2S/c1-3-19(11-6-4-7-12(10-11)21-2)16-18-14(20)13-8-5-9-17-15(13)22-16/h4-10H,3H2,1-2H3

Standard InChI Key:  KLKVAGUJXXVXID-UHFFFAOYSA-N

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 313.38Molecular Weight (Monoisotopic): 313.0885AlogP: 3.22#Rotatable Bonds: 4
Polar Surface Area: 55.32Molecular Species: NEUTRALHBA: 6HBD: 0
#RO5 Violations: 0HBA (Lipinski): 5HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 0.01CX LogP: 3.14CX LogD: 3.14
Aromatic Rings: 3Heavy Atoms: 22QED Weighted: 0.74Np Likeness Score: -1.48

References

1. Inami H, Shishikura J, Yasunaga T, Ohno K, Yamashita H, Kato K, Sakamoto S..  (2015)  Synthesis, structure-activity relationships, and anticonvulsant activities of 2-amino-4H-pyrido[3,2-e][1,3]thiazin-4-one derivatives as orally active AMPA receptor antagonists.,  23  (8): [PMID:25792143] [10.1016/j.bmc.2015.02.033]

Source